RFXANK

Across TCGA pan-cancer cohorts, RFXANK Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RFXANK data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RFXANK Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RFXANK expression acts as an unfavorable survival marker.

BLCA and SKCM are the cancer types where RFXANK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.083	0.626	<.001	24	view →
SKCM	OS	Median	II,III,IV	0.233	0.739	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RFXANK–BLCA (DFS)

Open the BLCA breakdown →